- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.01. | Jyong Biotech Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 19.12.25 | Jyong Biotech addresses share price fluctuations amid lock-up expiry | 2 | Investing.com | ||
| 19.12.25 | Jyong Biotech Ltd.: Jyong Biotech Responds to Share Price and Volume Movement | 221 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech") notes the recent fluctuation in its share price and the increased trading... ► Artikel lesen | |
| 04.12.25 | Jyong Biotech Ltd.: Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry | 224 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 24.11.25 | Jyong Biotech signs letter of intent with South Korean pharma company | 3 | Investing.com | ||
| 24.11.25 | Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs | 334 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| JYONG BIOTECH Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes | 269 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 29.09.25 | Jyong Biotech Ltd.: Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards | 2 | GlobeNewswire (USA) | ||
| 18.09.25 | Jyong Biotech Ltd.: Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei | 10 | GlobeNewswire (USA) | ||
| 16.09.25 | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | 423 | GlobeNewswire (Europe) | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| 22.08.25 | Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP) | 4 | GlobeNewswire (USA) | ||
| 17.06.25 | Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering | 447 | GlobeNewswire (Europe) | New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the "Company"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,365 | -2,29 % | Märkte am Morgen: Qiagen, Klöckner & Co., Netflix, 3M, Johnson & Johnson | Die Zollankündigungen von Donald Trump haben den deutschen Aktienmarkt weiter im Griff. Nach den Verlusten vom Montag gab der DAX auch gestern deutlich ab. Am Ende lag er 1,03 Prozent tiefer bei 24.703... ► Artikel lesen | |
| BIONTECH | 100,30 | +1,11 % | 6 Mittel in Pipeline: BioNTech: Diese bahnbrechende Nachricht läutet Rallye ein | © Foto: wallstreetonline/KI - OpenAIBioNTech meldet sich mit einem Kursfeuerwerk zurück. Mit einer neuen Fast-Track-Zulassung der FDA und einer strategischen Neuausrichtung auf die Krebsforschung bahnt... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,180 | +3,49 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| BIOMX | 7,375 | +74,76 % | Morning Market Movers: Nuwellis, BiomX, Brand Engagement Network, Blaize Holdings See Big Swings | WOONSOCKET (dpa-AFX) - At 7:02 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 306,24 | +4,15 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| ERASCA | 9,840 | +2,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,615 | +0,54 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| IMMUNITYBIO | 5,098 | -2,37 % | ImmunityBio-Aktie: Jetzt noch mit der Kursrakete mitfliegen? | Die ImmunityBio-Aktie machte einen Raketenstart ins neue Jahr. Bis gestern schoss der Kurs des Biotech-Unternehmens von 2,00 auf 5,50 US$ hoch. Doch am Dienstagmorgen bricht der Biotech-Titel im europäischen... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 90,19 | +0,60 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| ALUMIS | 26,260 | -0,19 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| RELAY THERAPEUTICS | 8,320 | +9,62 % | Oppenheimer upgrades Relay Therapeutics stock rating on gedatolisib concerns | ||
| ARCELLX | 68,41 | -0,20 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| MODERNA | 41,040 | +1,62 % | Opening Bell: Intel, Micron Technology, Lockheed Martin, Alibaba, Moderna, Lynas, Netflix | Die US-Börsen haben am Mittwoch kräftig zugelegt. Der Dow Jones stieg 1,21 Prozent, der Nasdaq Composite gewann 1,18 Prozent hinzu. Kurstreiber war ein politisches Signal: US-Präsident Donald Trump... ► Artikel lesen | |
| NUVALENT | 105,82 | -0,18 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen |
Das Unternehmen JYONG BIOTECH LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,850 Euro und damit -4,68 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JYONG BIOTECH LTD finden Sie auf Wallstreet Online.